Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up
Article 2020 en
Authors
MK
Monika Kozieł
MM
Michał Mazurek
CT
Christine Teutsch
Abstract
1 min read
Drug persistence was higher with NOACs (1-year persistence was 80%) than with VKAs (75%). There was little difference in 1-year persistence between NOAC dosing regimens.
Jan Steffel, Peter Verhamme, Tatjana Potpara, Pierre Albaladejo, Matthias Antz, Lien Desteghe, Karl Georg Hæusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldán, Nigel Rowell, Peter Sinnaeve, Rónán Collins, A. John Camm, Hein Heidbüchel, Professor Gregory Lip, Jeffrey I. Weitz, Laurent Fauchier, Deirdre A. Lane, Giuseppe Boriani, Andreas Goette,
Discussion(0)
No comments yet. Be the first to comment.